Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trials in Nashville, Tennessee

3 studies are recruiting for metastatic head and neck squamous cell carcinoma in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

    Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, r…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Site#0126, Nashville, Tennessee
    Locations
    203 in total
    Run by
    Bicara Therapeutics

    See if you can join NCT06788990 on ClinicalTrials.gov

  2. Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

    This Phase I, single-institution, open-label study will evaluate the safety, tolerability, and diagnostic performance of [18F]NOTA-ABY030 PET/CT in patients with head and neck squamous cell carcinoma (HNSCC) who present with indeterminate lesions on standard imaging. The investigational agent is a …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University Medical Center, Nashville, Tennessee
    Run by
    Vanderbilt-Ingram Cancer Center

    See if you can join NCT07217028 on ClinicalTrials.gov

  3. (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

    The goal of this phase I clinical trial is to evaluate the usefulness of an imaging test (zirconium Zr89 panitumumab [89Zr panitumumab]) with positron emission tomography (PET)/computed tomography (CT) for diagnosing the spread of disease from where it first started (primary site) to other places i…

    Stage
    Phase 1
    Ages
    19 and older
    Site
    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
    Run by
    Eben Rosenthal

    See if you can join NCT05747625 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.